EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Ariel Rechtman, Tal Freidman-Korn, Omri Zveik, Lyne Shweiki, Garrick Hoichman, Adi Vaknin-Dembinsky

Journal of Neurology · 2024-08 · 271 (8) · 5102-5108

DOI: 10.1007/s00415-024-12438-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurology, online erschienen am 29.05.2024. Verfasst von Ariel Rechtman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Medical Center, E…. Hauptthemen laut MEDLINE: Myelin-Oligodendrocyte Glycoprotein. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebrew University of Jerusalem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified demyelinating disorder with a diverse clinical spectrum. Diagnosing MOGAD traditionally relies on clinical judgment, highlighting the necessity for precise diagnostic criteria. Banwell et al. proposed criteria, aiming to refine the diagnostic spectrum. This study evaluates these criteria in a real-life cohort, comparing their performance with clinical judgment and describe the cohort of MOGAD patients.

Methods

This retrospective study, conducted at Hadassah Medical Center, included 88 patients with MOG-IgG antibodies. Patients with a positive or borderline MOG-IgG antibodies by cell-based assay were included. Demographics, clinical and MRI data were recorded. Cases were divided into definite MOGAD and Non-MOGAD groups as determined by the treating physician. We assessed the sensitivity and specificity of the new criteria in comparison to treating physicians’ evaluations. Additionally, we examined clinical differences between the MOGAD and Non-MOGAD groups.

Results

We observed a strong concordance (98%) between the new MOGAD criteria and treating physicians' diagnoses. Clinical disparities between MOGAD and Non-MOGAD groups included lower EDSS scores, normal MRI scans, preserved brain volume, negative OCB results, and distinct relapse patterns. Also, compared to relapsing patients, monophasic MOGAD patients have greater brain volume and a lower age at onset.

Conclusion

The study demonstrates robust accuracy of new MOGAD criteria, emphasizing their potential to enhance diagnostic precision. Treatment response integration into the MOGAD diagnosis is crucial, as it could aid in distinguishing MOGAD from other demyelinating disorders. Distinct clinical profiles highlight the importance of informed decisions in managing MOGAD and similar disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelin-Oligodendrocyte GlycoproteinHumansMaleFemaleRetrospective StudiesAdultMiddle AgedAutoantibodiesSensitivity and SpecificityMagnetic Resonance ImagingDemyelinating Autoimmune Diseases, CNSYoung Adult

Stichwörter der Autor:innen

DiagnosisMOG-IgGMOGADVolumetry

Substanzen

Myelin-Oligodendrocyte GlycoproteinAutoantibodiesMOG protein, human

Autor:innen und Institutionen

  • Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Medical Center, Ein-Kerem, Germany.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Medical Center, Ein-Kerem, Germany. adembinsky@gmail.com.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. adembinsky@gmail.com.
  • Neurology Department, Multiple Sclerosis and Immunobiology Research, Hadassah Medical Center, Ein-Kerem, POB 12000, 91120, Jerusalem, Israel. adembinsky@gmail.com.

Förderung

  • Hebrew University of Jerusalem

Zitieren

APA

Rechtman, A., Freidman-Korn, T., Zveik, O., Shweiki, L., Hoichman, G., & Vaknin-Dembinsky, A. (2024). Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings. Journal of Neurology, 271(8), 5102-5108. https://doi.org/10.1007/s00415-024-12438-6

Vancouver

Rechtman A, Freidman-Korn T, Zveik O, Shweiki L, Hoichman G, Vaknin-Dembinsky A. Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings. Journal of Neurology. 2024;271(8):5102-5108. doi:10.1007/s00415-024-12438-6

BibTeX
@article{Rechtman2024,
  author = {Rechtman, Ariel and Freidman-Korn, Tal and Zveik, Omri and Shweiki, Lyne and Hoichman, Garrick and Vaknin-Dembinsky, Adi},
  title = {Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings},
  journal = {Journal of Neurology},
  year = {2024},
  volume = {271},
  number = {8},
  pages = {5102--5108},
  doi = {10.1007/s00415-024-12438-6}
}
Kostenlos starten →